• Revenue increased by 22% to $477.3 million
• Net profit of $38.3 million compared to a loss of $2.3 million in H1 2025
• Strategic collaboration with Regeneron Pharmaceuticals for radiopharmaceutical therapies
• Expansion of manufacturing and distribution capabilities

Telix Pharmaceuticals Ltd reported strong financial results for the half-year ended June 30, 2026, with total revenue increasing by 22% to $477.3 million compared to $390.4 million in the same period last year. The company reported a net profit of $38.3 million, a significant improvement from the loss of $2.3 million in H1 2025. The growth was driven by increased demand for Illuccix and Gozellix in the U.S. and contributions from RLS Radiopharmacies. Telix also announced a strategic collaboration with Regeneron Pharmaceuticals to develop and commercialize next-generation radiopharmaceutical therapies. Additionally, the company expanded its manufacturing and distribution capabilities, including opening a new facility in partnership with the Melbourne Theranostic Innovation Centre.

Revenue expected to grow by 20-25% for FY26

Telix Pharmaceuticals expects continued revenue growth driven by the success of Illuccix and Gozellix, the launch of new imaging agents, and the advancement of its therapeutic pipeline.